Related Experiment Video
Updated: Jul 16, 2026
07:10
Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Lamivudine treatment for acute severe hepatitis B: a pilot study
H Schmilovitz-Weiss1, Z Ben-Ari, E Sikuler
1Gastroenterology Unit, Rabin Medical Center, Golda Campus, Israel.
Summary
Lamivudine treatment for severe acute hepatitis B in immunocompetent adults showed rapid clinical and virological responses. This antiviral therapy may prevent progression to fulminant or chronic hepatitis.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Limited data exists on lamivudine treatment for immunocompetent individuals with acute hepatitis B.
- Severe acute hepatitis B virus (HBV) infection can lead to serious complications.
Purpose of the Study:
- To assess the safety and efficacy of lamivudine in treating acute severe HBV infection in immunocompetent adults.
Main Methods:
- Fifteen immunocompetent adults with severe acute HBV infection received lamivudine (100 mg daily) for 3-6 months.
- Patients presented with encephalopathy, severe coagulopathy, high HBV DNA levels, and elevated liver enzymes.
Main Results:
- 86.6% of patients responded to lamivudine, with rapid improvement in encephalopathy and coagulopathy.
- Viral load (HBV DNA) became undetectable within 4 weeks, and liver enzymes normalized within 8 weeks.
- HBeAg-positive patients achieved seroconversion, and HBsAg became undetectable in all tested patients.
Conclusions:
- Lamivudine demonstrated prompt clinical, biochemical, serological, and virological responses in severe acute HBV.
- The antiviral medication may prevent progression to fulminant or chronic hepatitis, warranting its consideration in selected patients.
- Further large-scale randomized controlled trials are recommended.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...